Femasys (FEMY) Stock Analysis: AI Score & Alternative Data
Demand signals are heating up for Femasys
Is Femasys a buy right now? The alternative data says hold. This FEMY stock analysis is built on the 25+ alternative data signals AltIndex tracks on Femasys every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 47/100: a Hold. The stock trades at $2.29 with a $7M market cap.
The data leans positive over the past 90 days — web traffic up 40.5% to 6K monthly visits — but the move hasn’t been broad enough to lift FEMY into buy territory yet.
FEMY’s broader alt-data profile also covers headcount (61 employees, according to LinkedIn), X followers (308), Reddit mentions (1 a day), and sentiment (100/100). Every signal links to its own page with full history, the FEMY technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on FEMY is just below.
Femasys AI Stock Analysis
Femasys is a women’s healthcare company focused on providing innovative medical solutions in the US and internationally. The company develops products to address underserved areas in the female reproductive health market, enhancing the quality of care for women globally.
Analysis generated August 1, 2026.
Recent Femasys Stock Alerts
|
Femasys | August 12 Price is up by 8.1% in the last 24h. |
|
Femasys | August 10 Price is up by 6.4% in the last 24h. |
|
Femasys | August 7 Price is down by -7.1% in the last 24h. |
|
Femasys | August 4 Price is up by 6.1% in the last 24h. |
Femasys Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 6K | 40.5% | |
| LinkedIn Employees | 61 | 3.2% | |
| Employee Recommend | 0 | N/A | |
| Business Outlook | 0 | N/A | |
| Sentiment | 100 | 0% | |
| Reddit Mentions | 1 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 75 | 158.6% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 4K | 0.8% | |
| X Followers | 308 | 0.7% | |
| Facebook Followers | 163 | 3.8% | |
| Facebook Engagement | 0 | 100.0% |
About Femasys (FEMY)
Femasys Inc. is a pioneering medical technology company dedicated to revolutionizing women's healthcare through its advanced proprietary solutions for diagnosing and treating gynecological conditions. The company is noted for its innovative flagship products that provide non-surgical alternatives for prevalent issues such as uterine fibroids and contraception, firmly establishing itself as a leader in the dynamic women's health landscape. As the demand for minimally invasive treatments escalates, Femasys is well-positioned to leverage this trend, delivering enhanced patient outcomes and improving healthcare efficiency. With a strong commitment to addressing substantial unmet needs in women’s health, Femasys seeks to transform the standards of care within this essential sector.
| Price | $2.29 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $7M |
| Year Range | $2 – $21 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Medical & Dental Instruments |
Latest Femasys News
View more →
Femasys Secures $30 Million Private Placement, with Potential Proceeds of Up to $90 MillionAugust 7 - GlobeNewswire |
|
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterMay 13 - GlobeNewswire |
|
Global Zinc Mining Outlook to 2035: Production, Reserves, Prices, Trade and Major ProjectsAugust 7 - GlobeNewswire |
|
Global HPV Vaccines Market to Grow Rapidly at a CAGR of ~8% by 2034 | DelveInsightJune 24 - GlobeNewswire |
|
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsightMay 14 - GlobeNewswire |
Femasys Earnings & Financial Performance
View all earnings →Femasys Insider Trading Activity
View all →| No recent insider transactions on file. |
Femasys Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Femasys
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Innovative EyewearLUCY |
$0.73 2.7% | $6M | 52 |
 |
NexGelNXGL |
$0.57 15.6% | $5M | 42 |
 |
GlucoTrackGCTK |
$0.37 0.5% | $5M | 49 |
 |
Retractable TechnologiesRVP |
$0.69 2.0% | $21M | 40 |
 |
Milestone ScientificMLSS |
$0.50 10.5% | $44M | 48 |
Explore Femasys Data
Frequently Asked Questions: Femasys (FEMY)
Femasys has an AltIndex AI Score of 47/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
47/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Femasys (FEMY) stock is $2.29 with a market cap of $7M.
As of today, Femasys’s PE (Price to Earnings) ratio is —.
View the latest Femasys insider transactions to see recent buying and selling activity by company executives and directors.
Check the Femasys congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The FEMY stock price chart above shows Femasys’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Femasys technical analysis for RSI, moving averages, and more.
See the stocks similar to Femasys section on this page for companies in the same industry ranked by market cap and AI Score.
